Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer

Antioxidants and Redox Signaling

Volumn 23, Issue 1, 2015, Pages 15-29

  Chiaradonna, Ferdinando ^a,b   Barozzi, Iros ^c   Miccolo, Claudia ^c   Bucci, Gabriele ^c   Palorini, Roberta ^a,b   Fornasari, Lorenzo ^c   Botrugno, Oronza A ^c   Pruneri, Giancarlo ^c   Masullo, Michele ^c   Passafaro, Alfonso ^c   Galimberti, Viviana E ^c   Fantin, Valeria R ^d   Richon, Victoria M ^e   Pece, Salvatore ^c   Viale, Giuseppe ^c   Di Fiore, Pier Paolo ^c   Draetta, Giulio ^f   Pelicci, Pier Giuseppe ^c   Minucci, Saverio ^c,g   Chiocca, Susanna ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SYSBIO Centre of Systems Biology   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e Sanofi Oncology   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE 3; GLUTATHIONE REDUCTASE; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; OXIDOREDUCTASE; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CELL ADHESION; CELL DEATH; CELL GROWTH; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUTATHIONE METABOLISM; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; MCF 7 CELL LINE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIMARY CULTURE; PRIORITY JOURNAL; UPREGULATION; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; OXIDATION-REDUCTION; PRIMARY CELL CULTURE;

EID: 84934894856     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6189     Document Type: Article

References (76)

1. Alcarraz-Vizan G, Boren J, Lee WN, and Cascante M. Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation. Metabolomics 6: 229-237, 2010.
2. Altucci L and Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur J Cancer 45: 1137-1145, 2009.
3. Amoedo ND, Rodrigues MF, Pezzuto P, Galina A, da Costa RM, de Almeida FC, El-Bacha T, and Rumjanek FD. Energy metabolism in H460 lung cancer cells: effects of histone deacetylase inhibitors. PLoS One 6: e22264, 2011.
4. Bard S, Noel P, Chauvin F, and Quash G. Gamma-glutamyltranspeptidase activity in human breast lesions: an unfavourable prognostic sign. Br J Cancer 53: 637-642, 1986.
5. Basu HS, Mahlum A, Mehraein-Ghomi F, Kegel SJ, Guo S, Peters NR, and Wilding G. Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol 67: 705-715, 2011.
6. Botta D, White CC, Vliet-Gregg P, Mohar I, Shi S, McGrath MB, McConnachie LA, and Kavanagh TJ. Modulating GSH synthesis using glutamate cysteine ligase transgenic and gene-targeted mice. Drug Metab Rev 40: 465-477, 2008.
7. Brocker C, Cantore M, Failli P, and Vasiliou V. Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. Chem Biol Interact 191: 269-277, 2011.
8. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, and Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700-11705, 2002.
9. Carlisi D, Lauricella M, D'Anneo A, Buttitta G, Emanuele S, di Fiore R, Martinez R, Rolfo C, Vento R, and Tesoriere G. The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells. J Cell Physiol 230: 1276-1289, 2015.
10. Chiaradonna F, Cirulli C, Palorini R, Votta G, and Alberghina L. New insights into the connection between histone deacetylases, cell metabolism, and cancer. Antioxid Redox Signal 23: 30-50, 2015.
11. Cleary AS, Leonard TL, Gestl SA, and Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508: 113-117, 2014.
12. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G, Pece S, and Di Fiore PP. NUMB controls p53 tumour suppressor activity. Nature 451: 76-80, 2008.
13. Corti A, Franzini M, Paolicchi A, and Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 30: 1169-1181, 2010.
14. Cossarizza A, Ferraresi R, Troiano L, Roat E, Gibellini L, Bertoncelli L, Nasi M, and Pinti M. Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry. Nat Protoc 4: 1790-1797, 2009.
15. Cui X, Schiff R, Arpino G, Osborne CK, and Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23: 7721-7735, 2005.
16. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, and Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 39: 335-345, 2007.
17. Dawson MA and Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27, 2012.
18. Erejuwa OO, Sulaiman SA, and Ab Wahab MS. Evidence in support of potential applications of lipid peroxidation products in cancer treatment. Oxid Med Cell Longev 2013: 931251, 2013.
19. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M, and Kristiansen G. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8: 381, 2008.
20. Gabrielson M and Tina E. The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines. Oncol Rep 29: 1268-1274, 2013.
21. Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, and Bates SE. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 10: 997-1008, 2010.
22. Grant S, Easley C, and Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 6: 21-22, 2007.
23. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, De-Fazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, and Stratton MR. Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158, 2007.
24. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, and Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 116: 2732-2741, 2010.
25. Huang L, Sowa Y, Sakai T, and Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712-5719, 2000.
26. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, and Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 42: D199-D205, 2014.
27. Kitamura T, Takagi S, Naganuma T, and Kihara A. Mouse aldehyde dehydrogenase ALDH3B2 is localized to lipid droplets via two C-terminal tryptophan residues and lipid modification. Biochem J 465: 79-87, 2015.
28. Komatsu S, Moriya S, Che XF, Yokoyama T, Kohno N, and Miyazawa K. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochem Biophys Res Commun 437: 41-47, 2013.
29. Li Y, Li S, Chen J, Shao T, Jiang C, Wang Y, Chen H, Xu J, and Li X. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes. Human molecular genetics 23: 5378-5393, 2014.
30. Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, Nurnberg P, Mann NP, Banerjee R, Saka HN, Chapple JP, King PJ, Clark AJ, and Metherell LA. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet 44: 740-742, 2012.
31. Meister A and Anderson ME. Glutathione. Annu Rev Biochem 52: 711-760, 1983.
32. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M, Motoyama S, and Ogawa J. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 74: 300-304, 2011.
33. Minucci S and Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev Cancer 6: 38-51, 2006.
34. Moser MA, Hagelkruys A, and Seiser C. Transcription and beyond: the role of mammalian class I lysine deacetylases. Chromosoma 123: 67-78, 2014.
35. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
36. Nguyen VD, Saaranen MJ, Karala AR, Lappi AK, Wang L, Raykhel IB, Alanen HI, Salo KE, Wang CC, and Ruddock LW. Two endoplasmic reticulum PDI peroxidases increase the efficiency of the use of peroxide during disulfide bond formation. J Mol Biol 406: 503-515, 2011.
37. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, and Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14: 249-256, 1996.
38. Park S, Park JA, Kim YE, Song S, Kwon HJ, and Lee Y. Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells. Cell Stress Chaperones 20: 149-157, 2015.
39. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, Zurrida S, Maisonneuve P, Viale G, and Di Fiore PP. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 167: 215-221, 2004.
40. Pellatt AJ, Wolff RK, John EM, Torres-Mejia G, Hines LM, Baumgartner KB, Giuliano AR, Lundgreen A, and Slattery ML. SEPP1 influences breast cancer risk among women with greater native American ancestry: the Breast Cancer Health Disparities Study. PLoS one 8: e80554, 2013.
41. Petruccelli LA, Dupere-Richer D, Pettersson F, Retrouvey H, Skoulikas S, and Miller WH, Jr. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 6: e20987, 2011.
42. Polyak K and Marusyk A. Cancer: clonal cooperation. Nature 508: 52-53, 2014.
43. Poole RM. Belinostat: first global approval. Drugs 74: 1543-1554, 2014.
44. Rangwala S, Zhang C, and Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 4: 471-486, 2012.
45. Ronzoni S, Faretta M, Ballarini M, Pelicci P, and Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 66: 52-61, 2005.
46. Rosato RR and Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 9: 809-824, 2005.
47. Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, Chen W, Knapp W, and Zlabinger GJ. A microplate assay for the detection of oxidative products using 2′,7′-dichlorofluorescin-diacetate. J Immunol Methods 156: 39-45, 1992.
48. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, and Johnstone RW. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a celldeath pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98: 10833-10838, 2001.
49. Rushmore TH and Pickett CB. Glutathione S-transferases, structure, regulation, and therapeutic implications. J Biol Chem 268: 11475-11478, 1993.
50. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG, Chiocca S, Johnstone RW, and Minucci S. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121: 3459-3468, 2013.
51. Schulz GE, Schirmer RH, Sachsenheimer W, and Pai EF. The structure of the flavoenzyme glutathione reductase. Nature 273: 120-124, 1978.
52. Segre CV and Chiocca S. Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2011: 690848, 2011.
53. Spiegel S, Milstien S, and Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31: 537-551, 2012.
54. Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, Lange J, Cheng Z, Slater SA, Jeter SC, Powers P, Briest S, Chao C, Yoshizawa C, Sugar E, Espinoza-Delgado I, Sukumar S, Gabrielson E, and Davidson NE. Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. Clin Cancer Res 19: 4008-4016, 2013.
55. Tabas-Madrid D, Nogales-Cadenas R, and Pascual-Montano A. GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res 40: W478-W483, 2012.
56. Tanner KG, Landry J, Sternglanz R, and Denu JM. Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci U S A 97: 14178-14182, 2000.
57. Thakkar AD, Raj H, Chakrabarti D, Ravishankar, Saravanan N, Muthuvelan B, Balakrishnan A, and Padigaru M. Identification of gene expression signature in estrogen receptor positive breast carcinoma. Biomark Cancer 2: 1-15, 2010.
58. Tina E, Lindqvist BM, Gabrielson M, Lubovac Z, Wegman P, and Wingren S. The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors. BMC Cancer 12: 350, 2012.
59. Townsend DM and Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375, 2003.
60. Wang F and Yang Y. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat 147: 203-210, 2014.
61. Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J, Li H, Xie L, Zhao W, Yao Y, Ning ZB, Zeng R, Xiong Y, Guan KL, Zhao S, and Zhao GP. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 327: 1004-1007, 2010.
62. Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, Newgard CB, and McDonnell DP. Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23: 388-401, 2009.
63. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280: 168-176, 2009.
64. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, and Rocken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148, 2008.
65. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, and Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98: 604-610, 2008.
66. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, and Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res: 14: 1669-1677, 2008.
67. Wolf IM, Fan Z, Rauh M, Seufert S, Hore N, Buchfelder M, Savaskan NE, and Eyupoglu IY. Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration. Sci Rep 4: 6226, 2014.
68. Xiao W, Zhu Y, Sarsour EH, Kalen AL, Aykin-Burns N, Spitz DR, and Goswami PC. Selenoprotein P regulates 1-(4-Chlorophenyl)-benzo-2,5-quinone-induced oxidative stress and toxicity in human keratinocytes. Free Radic Biol Med 65: 70-77, 2013.
69. Yang XJ and Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9: 206-218, 2008.
70. You BR and Park WH. Suberoyl bishydroxamic acid-induced apoptosis in HeLa cells via ROS-independent, GSH-dependent manner. Mol Biol Rep 40: 3807-3816, 2013.
71. You BR and Park WH. Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner. Int J Oncol 42: 359-366, 2013.
72. Zhang C, Richon V, Ni X, Talpur R, and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125: 1045-1052, 2005.
73. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S, and Iwase H. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10: 6962-6968, 2004.
74. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L, Zeng Y, Li H, Li Y, Shi J, An W, Hancock SM, He F, Qin L, Chin J, Yang P, Chen X, Lei Q, Xiong Y, and Guan KL. Regulation of cellular metabolism by protein lysine acetylation. Science 327: 1000-1004, 2010.
75. Zhu Y, Das K, Wu J, Lee MH, and Tan P. RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells. Oncogene 33: 1527-1537, 2014.
76. Zhuo P and Diamond AM. Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim Biophys Acta 1790: 1546-1554, 2009.